-
Blood: All-trans retinoic acid + low-dose rituximab in the treatment of refractory/relapsed immune thrombocytopenia
Time of Update: 2021-12-01
All-trans retinoic acid combined with low-dose rituximab can significantly improve the overall remission rate and sustained remission rate of patients with hormone refractory or recurrent immune thrombocytopenia, suggesting that the combination therapy may become such refractory Potential options for patients .
-
LEUKEMIA: Poor results of COVID-19 patients after CAR T cell treatment of B-cell malignancies
Time of Update: 2021-12-01
CAR-TIllness duration is defined as the time from diagnosis of COVID-19 to resolution of the disease, defined as a negative PCR test or regression or death based on clinical findings .
-
HAEMATOLOGICA: The negative prognostic impact that persists in the early stages of acute myeloid leukemia can be overcome by obtaining a response after induction and before treatment
Time of Update: 2021-12-01
A study was conducted in a large number of intensively treated AML patients (n=1008) to analyze the prognostic effects of early explosive clearance on OS, EFS, and RFS, and to evaluate the long-term prognosis of patients with persistent early explosives .
-
BJH: The specificity of the manifestations and treatment of primary immune thrombocytopenia in elderly patients
Time of Update: 2021-12-01
The purpose of a foreign study is to evaluate the clinical manifestations and management of primary ITP in very elderly patients (VEPs: age ≥ 80 years) and elderly patients (EPs: age 65-79 years), and to determine risk factors for bleeding at the initial presentation .
-
AJH: Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploid peripheral blood stem cell transplantation
Time of Update: 2021-12-01
0363) (created by EZR (Saitama Medical Center, Saitama Medical University, Japan)) Figure 3 ：A, the cumulative incidence of total remission in patients with myelodysplasia (n=27) and patients with bone marrow hypoplasia (n=7) (P=0.
-
J clin oncol: The influence of donor clonal hematopoiesis on the clinical prognosis of hematopoietic cell transplant recipients
Time of Update: 2021-12-01
2%); 85% of donor clones are implanted in the recipient for a long time after transplantation , including variant allele frequencies <0.
-
Blood: Use CAR T cell therapy (liso-cel) to treat relapsed/refractory CLL/SLL
Time of Update: 2021-12-01
In this study, standard or high-risk CLL/SLL patients who had been treated more than two or three times (including BTKi) received two doses of liso-cel (50×106 or 100×106 CAR+ T cells) .
-
NEJM: Merck's ROR1 ADC demonstrates the potential of lymphoma treatment
Time of Update: 2021-12-01
. At this time, Zilovtamab vedotin has conducted a phase I clinical trial for hematological tumors (the first dose increase study in humans), and the results of this study were published on NEJM .
-
LEUKEMIA: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance treatment for myeloma up to 70 years old
Time of Update: 2021-12-01
German Myeloma Multicenter Group (GMMG)-MM5 is a prospective, multicenter Phase III trial using bortezomib-based IT, pre-MEL200/ASCT and lenalidomide consolidation and maintenance for patients 18 to 70 years old Treatment, an analysis was performed, focusing on progression-free survival (PFS), overall survival (OS), time to progression (TTP), non-relapse mortality (NRM), response rate, and patient age-related toxicity .
-
Blood: Prevention of recurrent thrombotic events in children with central venous catheter-related venous thrombosis
Time of Update: 2021-12-01
Central point: Children with a history of central venous catheter (CVC)-related thromboembolism are at increased risk of recurrence of venous thromboembolism; subsequent placement of central venous catheters using full-dose anticoagulation as secondary prevention is associated with a 65% reduction in thromboembolism .
-
Leukemia: Family history of plasma cell disease is associated with increased survival rates for MGUS, multiple myeloma, and systemic AL amyloidosis
Time of Update: 2021-12-01
This is the first study to prove that patients with a family history of PCD in the MGUS, MM, and systemic AL amyloidosis cohort have improved overall survival .
-
Research status of platelet-rich plasma (PRP) in the treatment of vitiligo
Time of Update: 2021-12-01
evaluated 80 cases of vitiligo patients with combined treatment of carbon dioxide laser, autologous PRP and narrow-band ultraviolet B for 12 months in different parts .
Combined treatment with fractional carbon dioxide laser, autologous platelet-rich plasma, and narrow band ultraviolet B for vitiligo in different body sites: a prospective, randomized comparative trial.
-
ACR 2021: What will happen to patients with rheumatoid arthritis "bumping" on ANCA positive and vasculitis?
Time of Update: 2021-12-01
result:25 patients (32%) were diagnosed with AAV; 9 (36%) microscopic polyangiitis (MPA), 8 (32%) granuloma with polyangiitis (GPA), 1 (4%) eosinophilic granuloma With polyangiitis (EGPA), 1 (4%) GPA and rheumatoid vasculitis (peripheral ulcerative keratitis, scleritis, sudden hearing loss, MPO positive) .
-
A case of allergic reaction caused by platelet transfusion
Time of Update: 2021-12-01
It usually occurs within a few minutes after blood transfusion, but can also occur during or immediately after blood transfusionMild: general skin itching, skin erythema, urticaria, angioedema (more common on the face) and joint pain, blood eosinophiliaSevere: bronchospasm, laryngeal mucosal edema, dyspnea, asthma, cyanosis, or even anaphylactic shockTreatment measures:Treatment measures:
-
Acta Haematologica: The normal value and unique morphological characteristics of neonatal cord blood
Time of Update: 2021-12-01
Left: The average standard deviation of birth weight, gestational age and APGAR5 of the samples in each groupFigure 3: Umbilical cord blood samples are classified by neonatal status .
-
Ann Hematol: POV-based salvage immunochemotherapy as a third-line or above treatment for patients with diffuse large B-cell lymphoma
Time of Update: 2021-12-01
Stem cells based on the revised International Prognostic Index score at the time of diagnosis and before PoV treatment, low/medium risk predicts better OS .
B: 21 patients achieved progression-free survival with complete or partial remissionFigure 1: A: Overall survival rate of 40 patients with relapsed/refractory DLBCL using pov-based treatment .
-
J Clin Oncol: Bonatumumab non-response and high disease burden suggest that B-ALL patients with CD19-CAR treatment have a poor prognosis
Time of Update: 2021-12-01
Bonatumumab treatment non-response and high disease burden are independently related to poor RFS and EFS after CD19-CAR treatment in B-ALL patients .
Bonatumumab treatment non-response and high disease burden are independently related to poor RFS and EFS after CD19-CAR treatment in B-ALL patients .
-
Haemophilia: Assessment of dental habits and oral health in children and adolescents with bleeding disorders
Time of Update: 2021-12-01
Evaluate the dental habits, needs, and oral health of pediatric patients with bleeding disorders, and determine predictors of poor oral health .
In summary, children with bleeding disorders usually have obvious dental lesions and report obstacles in dental care, posing a potential risk of disease .
-
HEMATOLOGICAL ONCOLOGY: Application of bronchoscopy to newly diagnosed patients with acute leukemia
Time of Update: 2021-12-01
Microbiology studies from BAL fluid and those obtained before bronchoscopy were classified as clinically significant or insignificant by retrospective infectious disease physicians (ML) .
-
AJH: Sutizumab can effectively prevent the exacerbation of hemolytic anemia in patients with cold agglutinin disease undergoing major surgery
Time of Update: 2021-12-01
A foreign research team described a white male who had a 10-year history of coronary heart disease (CHD), with three right coronary artery (RCA) stents for myocardial infarction as a manifestationSutizumab is a complement c1 inhibitor that can selectively block classic complement activation, but retains the alternative and lectin pathways .
